Corrigendum

Corrigendum to “Design of the NIDA clinical trials network validation study of tobacco, alcohol, prescription medications, and substance use/misuse (TAPS) tool” [Contemporary Clinical Trials. 2016 Jul. 19; 50: 90–97]

Li-Tzy Wu a,b,c,d,* Jennifer McNeely e, Geetha A. Subramaniam f, Gaurav Sharma g, Paul VanVeldhuisen e, Robert P. Schwartz h

a Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA
b Department of Medicine, Division of General Internal Medicine, Duke University Medical Center, Durham, NC, USA
c Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
d Center for Child and Family Policy, Duke University, Durham, NC, USA
e Department of Population Health, New York University School of Medicine, New York, NY, USA
f National Institute on Drug Abuse, Bethesda, MD, USA
g The EMMES Corporation, Rockville, MD, USA
h Friends Research Institute, Inc., Baltimore, MD, USA

In the article, we mistakenly stated that we drew select items from the World Health Organization’s Composite International Diagnostic Interview 2.0 (WHO CIDI-2.0) substance abuse module to assess substance use disorders. However, we actually used select items from the WHO World Mental Health-CIDI [WMH-CIDI]: http://www.hcp.med.harvard.edu/wmhcidi/index.php). Additionally, the DSM-5 has only one set of criteria for all substance use disorders, including tobacco. Because the WMH-CIDI does not contain all the criteria for DSM-5 Tobacco Use Disorder, we adapted the language from the WMH-CIDI items from the drug section to assess tobacco use disorder. Readers of our article should note the mislabeling “modified CIDI-2” in Fig. 1 and on page 95. The correct description should read “modified WMH-CIDI.” The authors would like to apologise for any inconvenience caused.